Abstract
Objective: To evaluate the impact of statins on carotid restenosis (CR) >50% and future cardiovascular events (CVE), in patients undergoing carotid endarterectomy (CEA).
Methods: 570 consecutive patients (656 CEAs) operated between 1990 and 2009, were included in this retrospective study. The study cohort was followed for an average of 82 months (median 80, range 12- 180 months). Endpoints were the development of CR >50%, the occurrence of CVE (myocardial infarction, stroke) and overall mortality. Kaplan-Meier curves and Cox regression models were used to assess outcomes.
Results: 92 restenosis events were recorded. Freedom from restenosis >50% at 5, 10 and 15 years of follow-up was 92, 82 and 69%, respectively. Compared with statin-receivers, statin-free patients had a significantly higher 15-year restenosis rate (41 vs 10%; P = .001), a significantly higher CVE rate (49 vs 14%; P = .001) and a significantly higher mortality rate (24 vs 18%; P = .034). Adjusting for other covariates statins were independently associated with lower restenosis rate (hazard ratio [HR], 0.52; 95% CI, 0.31-0.88; P= .016), cardiovascular events (HR, 0.40; 95% CI, 0.26-0.61; P < 0.001) and long-term mortality (HR, 0.56; 95% CI, 0.33-0.95; P = .032).
Conclusion: Statins not only reduce cardiovascular events and mortality but may also have an important effect on the anatomic durability of CEA. These data support the use of statins in patients with carotid stenosis undergoing CEA.
Keywords: Carotid endarterectomy, restenosis, mortality, echolucent plaque, statins.
Current Vascular Pharmacology
Title:Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Volume: 13 Issue: 2
Author(s): Efthymios D. Avgerinos, John D. Kakisis, Konstantinos G. Moulakakis, Triantafillos G. Giannakopoulos, George Sfyroeras, Constantinos N. Antonopoulos, Nikolaos P. Kadoglou and Christos D. Liapi
Affiliation:
Keywords: Carotid endarterectomy, restenosis, mortality, echolucent plaque, statins.
Abstract: Objective: To evaluate the impact of statins on carotid restenosis (CR) >50% and future cardiovascular events (CVE), in patients undergoing carotid endarterectomy (CEA).
Methods: 570 consecutive patients (656 CEAs) operated between 1990 and 2009, were included in this retrospective study. The study cohort was followed for an average of 82 months (median 80, range 12- 180 months). Endpoints were the development of CR >50%, the occurrence of CVE (myocardial infarction, stroke) and overall mortality. Kaplan-Meier curves and Cox regression models were used to assess outcomes.
Results: 92 restenosis events were recorded. Freedom from restenosis >50% at 5, 10 and 15 years of follow-up was 92, 82 and 69%, respectively. Compared with statin-receivers, statin-free patients had a significantly higher 15-year restenosis rate (41 vs 10%; P = .001), a significantly higher CVE rate (49 vs 14%; P = .001) and a significantly higher mortality rate (24 vs 18%; P = .034). Adjusting for other covariates statins were independently associated with lower restenosis rate (hazard ratio [HR], 0.52; 95% CI, 0.31-0.88; P= .016), cardiovascular events (HR, 0.40; 95% CI, 0.26-0.61; P < 0.001) and long-term mortality (HR, 0.56; 95% CI, 0.33-0.95; P = .032).
Conclusion: Statins not only reduce cardiovascular events and mortality but may also have an important effect on the anatomic durability of CEA. These data support the use of statins in patients with carotid stenosis undergoing CEA.
Export Options
About this article
Cite this article as:
Avgerinos D. Efthymios, Kakisis D. John, Moulakakis G. Konstantinos, Giannakopoulos G. Triantafillos, Sfyroeras George, Antonopoulos N. Constantinos, Kadoglou P. Nikolaos and Liapi D. Christos, Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy, Current Vascular Pharmacology 2015; 13 (2) . https://dx.doi.org/10.2174/15701611113119990130
DOI https://dx.doi.org/10.2174/15701611113119990130 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Vitamins and Cardiovascular Disease
Current Topics in Medicinal Chemistry Heart Failure in South America
Current Cardiology Reviews Effects of β-glucan and Folium mori Extract Combinations in STZ-induced Diabetic Rats: Effectiveness of Various BGFM Complex Compositions in Treating Diabetes
Current Nutrition & Food Science Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review
Current Pharmaceutical Design Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Current Diabetes Reviews Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms
Infectious Disorders - Drug Targets Influence of Glycation of Plasma Proteins in Diabetes on the Binding Interaction with Polyphenols
Current Drug Metabolism Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design Design of Bioartificial Pancreas with Functional Micro/Nano-Based Encapsulation of Islets
Current Pharmaceutical Biotechnology Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Computer Aided Drug Design Strategies Used in the Discovery of Fructose 1, 6-Bisphosphatase Inhibitors
Current Pharmaceutical Design Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Imaging in Diabetic Retinopathy: A Review of Current and Future Techniques
Current Diabetes Reviews